Section 232 Pharmaceutical Tariffs: What Importers Need to Do Right Now

A sweeping new tariff regime quietly took effect on July 31, 2026, and it carries some of the steepest rates in recent trade history. Under Presidential Proclamation 11020, U.S. Customs and Border Protection (CBP) began implementing Section 232 tariffs on certain patented pharmaceutical products and active pharmaceutical ingredients (APIs)—with rates reaching as high as 100%. If your company imports pharmaceuticals or pharmaceutical ingredients, the compliance clock is already ticking.

What the Section 232 Pharma Tariffs Cover

The tariffs stem from a national security investigation into U.S. dependence on imported patented pharmaceuticals. On April 2, 2026, the President issued Proclamation 11020, and CBP issued implementation guidance on July 30, 2026, with new Chapter 99 reporting requirements going live the very next day.

The measures apply to three categories of imports classified under affected HTSUS Chapter 29 and 30 provisions:

• Patented finished pharmaceutical products
• Active pharmaceutical ingredients (APIs) used in patented pharmaceuticals
• Certain key starting materials used in patented pharmaceuticals

Critically, generic pharmaceuticals, biosimilars, and their ingredients are excluded from the additional duties. Investigational pharmaceutical products used in clinical research are also generally unaffected. But for importers of branded, patented drugs and their upstream ingredients, this is a material change to landed cost calculations.

The Phased Rollout—and Why Reporting Matters Now

Implementation is phased based on manufacturer, and the structure has an important nuance that many importers are missing:

• July 31, 2026: Chapter 99 reporting requirements took effect for all covered importers. Every entry of an affected product must now include the correct Chapter 99 tariff provision on the entry summary—even if no additional duty is owed yet.
• September 29, 2026: The full tariff rates become payable for most importers, depending on manufacturer eligibility.

Country of origin matters significantly for the duty rate. The standard Section 232 tariff is 100%, but reduced rates apply to qualifying imports from the European Union, Japan, South Korea, Switzerland, and Liechtenstein (15%). Imports from the United Kingdom currently face a 0% rate under the U.S.-UK pharmaceutical agreement. U.S.-origin pharmaceutical products are excluded, as are qualifying U.S.-origin APIs that are packaged into finished dosage forms abroad—provided the importer has the supporting documentation to prove it.

This tiered structure means that classification, country of origin determination, and documentation management are all immediately critical—not just when the duty becomes payable in September.

Three Action Items for Pharma Importers Right Now

The window between now and September 29 is not a grace period to delay action—it's an opportunity to get ahead of a compliance obligation that is already partially in force. Here's what to do:

1. Review your HTS classifications. Confirm whether any of your products or ingredients fall under the affected HTSUS Chapter 29 or 30 provisions. The CBP guidance includes detailed product eligibility criteria. Misclassifying a covered product—or failing to classify it at all—can result in penalties and delays at port.
2. Apply the correct Chapter 99 provision on all entries today. This is not optional. CBP's July 30 implementation guidance makes clear that the reporting requirement is already active. Work with your customs broker to ensure every entry summary for covered goods includes the appropriate Chapter 99 tariff provision.
3. Audit your origin documentation. If you're importing from a country with a reduced rate—or if you believe your APIs qualify for a U.S.-origin exclusion—make sure you have the documentation to support that position before September 29. Origin determinations and exclusion claims require records, not just assertions.

How GLCHB Can Help

Tariff changes of this magnitude affect not just duty liability, but every layer of your import program—from HTS classification and entry preparation to post-entry audit and liquidation. At Guy Lichtenstein CHB Corp, we work with importers across the country to navigate exactly these kinds of fast-moving regulatory changes.

Whether you need a classification review for your pharmaceutical product line, help implementing Chapter 99 reporting on your current entries, or strategic guidance on managing duty exposure before the September 29 deadline, our team is ready. Contact GLCHB today to schedule a compliance review—before the full tariff burden takes effect.